Global Endogenous Peptide Substances Supply, Demand and Key Producers, 2023-2029

Global Endogenous Peptide Substances Supply, Demand and Key Producers, 2023-2029

The global Endogenous Peptide Substances market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The driving force of endogenous peptides mainly comes from the following aspects:

Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.

Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.

Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.

Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.

This report studies the global Endogenous Peptide Substances demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Endogenous Peptide Substances, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Endogenous Peptide Substances that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Endogenous Peptide Substances total market, 2018-2029, (USD Million)

Global Endogenous Peptide Substances total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Endogenous Peptide Substances total market, key domestic companies and share, (USD Million)

Global Endogenous Peptide Substances revenue by player and market share 2018-2023, (USD Million)

Global Endogenous Peptide Substances total market by Type, CAGR, 2018-2029, (USD Million)

Global Endogenous Peptide Substances total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Endogenous Peptide Substances market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Assertio Therapeutics Inc., Cipher Pharmaceuticals Inc., Endo International Plc, Biosynth Carbosynth, Lannett Co. Inc., Pfizer, Johnson & Johnson, Peptide Institute and Abbexa, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Endogenous Peptide Substances market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Endogenous Peptide Substances Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Endogenous Peptide Substances Market, Segmentation by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides

Global Endogenous Peptide Substances Market, Segmentation by Application
Research
Medicine
Others

Companies Profiled:
Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides

Key Questions Answered

1. How big is the global Endogenous Peptide Substances market?

2. What is the demand of the global Endogenous Peptide Substances market?

3. What is the year over year growth of the global Endogenous Peptide Substances market?

4. What is the total value of the global Endogenous Peptide Substances market?

5. Who are the major players in the global Endogenous Peptide Substances market?